Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.54 |
| ▸ | GSK3B | P49841 | 10/20 | 0.47 |
| ▸ | CDK2 | P24941 | 4/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | FBP1 | P09467 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2819322 | 0.98 | ADORA2A (0.56) | ADORA2AGSK3BCDK2MAPK14GAA | |
| SCHEMBL287658 | 0.84 | ADORA2A (0.74) | ADORA2AGSK3BGAAFBP1KDM4E | |
| SCHEMBL1166663 | 0.79 | KMT2A (0.56) | ADORA2AGSK3BCDK2GAAFBP1 | |
| SCHEMBL3758327 | 0.79 | ADORA2A (0.54) | ADORA2AGSK3BCDK2GAAFBP1 | |
| SCHEMBL20376680 | 0.79 | ADORA2A (0.54) | ADORA2AGSK3BCDK2GAAFBP1 | |
| SCHEMBL1167383 | 0.79 | GAA (0.68) | ADORA2AGSK3BGAAFBP1KDM4E | |
| SCHEMBL1167030 | 0.79 | ADORA2A (0.54) | ADORA2AGSK3BMAPK14GAAFBP1 | |
| SCHEMBL1167311 | 0.79 | GSK3B (0.60) | ADORA2AGSK3BGAAFBP1KDM4E | |
| SCHEMBL9722654 | 0.79 | GSK3B (0.55) | ADORA2AGSK3BCDK2GAAFBP1 | |
| SCHEMBL12479929 | 0.78 | ADORA2A (0.41) | ADORA2AGSK3BCDK2GAAFBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2242743-B1 | AMINOPYRAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-08-21 | — | — | EP | disclosed |
| US-8288419-B2 | Aminopyrazole derivatives | ACTELION PHARMACEUTICALS, LTD (CH) | 2012-10-16 | — | — | US | disclosed |
| US-20110034516-A1 | AMINOPYRAZOLE DERIVATIVES | ACTELION (CH) | 2011-02-10 | — | — | US | disclosed |
| CN-101903353-A | Aminopyrazole derivatives | ACTELION PHARMACEUTICALS LTD | 2010-12-01 | — | — | CN | disclosed |
| EP-2242743-A1 | AMINOPYRAZOLE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-10-27 | — | — | EP | disclosed |
| WO-2009077954-A1 | AMINOPYRAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034516-A1 | AMINOPYRAZOLE DERIVATIVES | CYP3A43, CYP1A2, CYP3A5 | ADORA2A 102/4885GSK3B 2540/4885CDK2 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.